exRNAdisease

General Information

Database ID:

exR0080613

RNA Name:

RPL5

RNA Type:

mRNA

Chromosome:

chr1

Starnd:

Coordinate:

Start Site(bp):

92832013

End Site(bp):

92841924

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABCB4	chr7	87401697	87480435	-
AC004922.1	chr7	99325879	99394653	+
AGTPBP1	chr9	85546539	85742029	-
ACO1	chr9	32384603	32454769	+
AL136454.1	chr1	192716132	192716653	+
ALDH18A1	chr10	95605941	95656711	-
ACTR3	chr2	113890063	113962596	+
ADSL	chr22	40346500	40390463	+
AC073896.1	chr12	56285916	56316059	-
AC015802.6	chr17	76563710	76570544	-
AC091167.2	chr15	90249556	90272208	+
AGK	chr7	141551278	141655244	+
ACIN1	chr14	23058564	23095614	-
AGO1	chr1	35869808	35930532	+
AASS	chr7	122073549	122144255	-
ABL1	chr9	130713016	130887675	+
AL022238.4	chr22	40346529	40410054	+
AL365273.2	chr10	95860548	95924844	+
ACP6	chr1	147629652	147670524	-
ACVR1B	chr12	51951699	51997078	+
ALDOA	chr16	30064164	30070457	+
ACTR2	chr2	65227753	65271253	+
AGA	chr4	177430774	177442437	-
AK2	chr1	33007940	33080996	-
AEN	chr15	88621337	88632281	+
ADNP2	chr18	80109262	80147523	+
AC073612.1	chr12	71674204	71698968	+
AL121594.1	chr14	35122549	35317474	+
ACTB	chr7	5527148	5563784	-
AGRN	chr1	1020120	1056118	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-3654	chr7	133034860	133034878	-
hsa-miR-4426	chr1	192716333	192716349	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC010163.1	chr10	78293842	78301003	+
AC018521.1	chr17	47945424	47981736	+
AC022167.2	chr16	8848105	8860456	+
AC024940.6	chr12	31280422	31280895	-
AC104461.1	chr1	200333193	200478669	+
AC132217.1	chr11	2129121	2129964	-
AC139149.1	chr17	81514047	81527776	+
AD000090.1	chr19	35557956	35581954	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference